PremiumRatingsEnanta Pharmaceuticals: Hold Rating Amid Delayed Launches and Strategic Advancements Enanta Pharmaceuticals Advances in Virology and Immunology Enanta CEO buys $256K in common stock PremiumThe FlyEnanta price target lowered to $18 from $27 at H.C. Wainwright Enanta price target lowered to $20 from $30 at Evercore ISI Enanta Pharmaceuticals Reports Promising Results for Pediatric RSV Drug PremiumThe FlyEnanta price target lowered to $21 from $22 at JMP Securities Enanta Pharmaceuticals Reports Q4 2024 Financials Closing Bell Movers: Semtech rises, Zoom falls after earnings 
